Study: Kidney Damage Diagnosis May Be Inaccurate for Many
Researchers from Columbia University Medical Center (CUMC) have found that, for many patients, an initial diagnosis of “acute kidney injury” may have been inaccurate. Their finding, published in Journal of the American Society of Nephrology, suggests that the current method of assessing kidney function may be misleading during the initial evaluation of a patient.
In a related Comment published in The Lancet, Jonathan Barasch, MD, PhD, professor of medicine and pathology and cell biology at CUMC, and colleagues Drs. Joseph Bonventre (Harvard Medical School, Brigham and Women’s Hospital) and Richard Zager (University of Washington Medicine) explain that the blood test, which measures serum creatinine — a waste product that is removed by the kidneys and excreted in urine — only offers a snapshot of the kidney’s function at a given moment, which can vary depending on individual factors such as body size and muscle mass.
Each year, an estimated 5-7 percent of patients admitted to hospitals in the U.S. and 30-50 percent of patients in critical or intensive care settings, are diagnosed with acute kidney injury (AKI). However, the true degree of injury cannot be known for many days because creatinine tests only provide a retrospective look at the kidney’s response to possible injury. In addition, the blood test can register “positive” for AKI even when the kidney may not have been injured.
“Nephrologists are trained to evaluate a constellation of factors in determining whether or not a patient has a condition that may temporarily affect kidney function, such as dehydration or heart failure, and to distinguish these temporary conditions from true kidney cell damage,” explained Dr. Barasch, one of the authors of the study. “But in a busy, time-pressured setting such as the emergency room or intensive care unit, doctors rely to a greater extent on the blood test used as a proxy for measuring kidney function in order to make an immediate diagnosis. Unfortunately, the initial creatinine tests can lead to misdiagnosis and inappropriate treatment.”
Misdiagnoses appear to be common, according to the researchers’ review of the electronic health records of 3.8 million emergency and intensive care patients. More than 61,000 diagnoses of AKI, as defined by rising creatinine level, were identified. Within three days, however, 73 percent of patients with an AKI diagnosis had creatinine levels that returned to normal, suggesting that many of these patients may not have had kidney damage.
In the study, the investigators sought a more reliable method of identifying patients with kidney damage. They looked for biomarkers to distinguish between kidney damage and a transient condition, both of which activate a rise in the creatinine blood test. The researchers performed genomic analyses of mice with kidney damage and those with dehydration and a similar rise in creatinine levels. Their analyses revealed more than a thousand biomarkers (proteins) distinguishing these two conditions, with minimal overlap.
Lead author Katherine Xu, a PhD candidate in Columbia’s Institute of Human Nutrition, stated: “Our ongoing studies may help to determine if these biomarkers can be deployed in the emergency or intensive care setting to improve the initial diagnosis and treatment plan when kidney damage is in doubt.”
Source: Columbia University Medical Center
Image Credit: Dan
«« The Importance of Correctly Identifying Patients with Sepsis
Published on : Tue, 28 Feb 2017
StatStrip® and StatStrip Xpress®2 Glucose Meters
The only glucose meters cleared by US FDA and Health Canada for use with all patients, including critically ill Because of the unacceptably high rate of adverse patient events, including deaths, linked to the point-of-care (POC) use of glucose...
Transport of ECLS patients
The Xenios MultiSupport GROUND (MSG) is a system consisting of different components, designed to enable inner- and inter-hospital transport of severely ill patients undergoing life-saving extracorporeal heart and lung support. As a whole, the Xenios...
Stat Profile Prime® ES Plus Analyzer
Not available in all markets Exceptional Simplicity in a New Generation Electrolyte Analyzer Introducing a new generation electrolyte analyzer that combines the revolutionary microelectronics of the consumer world with new microsensor...
IVD CAPSULE PSP
For Early Sepsis Detection
IVD CAPSULE PSP The IVD CAPSULE PSP is a rapid, single-use in vitro diagnostic test for the quantitative measurement of pancreatic stone protein (PSP) in blood. The test is intended to be used in conjunction with other clinical assessments and laboratory...
StatStrip® and StatStrip Xpress®2 Glucose/Ketone Meters
Not yet available in the U.S. The most extensively studied and proven glucose measurement technology In addition to studies submitted to the FDA, 168 other independent studies over the last eight years—including 53 critical care studies—have...